When analysis was restricted to stage I lung cancer, we found that the combined HR (2.51) was larger than the combined HR for all 10 eligible studies of stages I-III (1.68), suggesting that EZH2 expression could be an important prognostic factor for early-stage lung cancer. This evidence concerns the gene EZH2 and lung carcinoma.